Assertio Holdings Inc (ASRT) FinancialsASRTFinancialAssertio Holdings Inc

Assertio Holdings Inc (ASRT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is INDOCIN products, accounting for 34.7% of total sales, equivalent to $3.45M. Other significant revenue streams include Sympazan and SPRIX Nasal Spray. Understanding this composition is critical for investors evaluating how ASRT navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Assertio Holdings Inc maintains a gross margin of 14.28%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -185.95%, while the net margin is -189.83%. These profitability ratios, combined with a Return on Equity (ROE) of -38.76%, provide a clear picture of how effectively ASRT converts its operational activities into shareholder value.

In the context of the broader market, ASRT competes directly with industry leaders such as CRBP and PRQR. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, ASRT's gross margin of 14.28% stands against CRBP's N/A and PRQR's 100.00%. Such benchmarking helps identify whether Assertio Holdings Inc is trading at a premium or discount relative to its financial performance.

No usable latest-quarter financial snapshot was provided, so I cannot assess revenue or earnings growth trends for the most recent season. Based on the available data, there is no evidence here of a strong fundamental acceleration supporting a long-term buy thesis.